News | January 02, 2008

Abiomed Honors Tufts-New England Medical Center for Heart Recovery

January 3, 2008 – Abiomed Inc. selected Tufts-New England Medical Center (Tufts-NEMC) as a “Center of Excellence” for its cardiac program, having achieved outstanding clinical outcomes with the recovery of the native heart.

As a Center of Excellence, Tufts-NEMC will share best practices related to VAD implantation and patient care with other hospitals and medical centers. This award is granted to top institutions in the country for achieving significant clinical outcomes and their focus on recovery of the native heart. Tufts-NEMC’s outcomes are among the best in the country.

“Center of Excellence designation further exemplifies our commitment to native heart recovery and the total wellbeing of our patients,” said Afshin Ehsan, M.D., Division of Cardiothoracic Surgery at Tufts-NEMC. “Tufts-New England Medical Center’s continued success in recovering patients’ hearts, evidenced by the recovered patients able to join us today, is due to the clinical excellence and dedication of our entire cardiac team.”

Tufts-NEMC has supported more than 20 patients with Abiomed technologies. In addition, as the only Abiomed training center in New England, Tufts-NEMC conducts ongoing certification training for other hospitals.

Abiomed is a provider of medical technologies that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery, enabling the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart.

For more information: and

Related Content

Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Abiomed Receives FDA PMA Approval for Impella RP for Right Heart Failure
Technology | Ventricular Assist Devices (VAD) | September 28, 2017
Abiomed Inc. recently received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP ...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD) | August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Pre-PCI Impella 2.5 Insertion Improves Survival in Left Main Coronary Artery Heart Attacks
News | Ventricular Assist Devices (VAD) | June 30, 2017
Abiomed Inc. announced the recent publication of a peer-reviewed retrospective study on hemodynamic support with the...
Overlay Init